- Home
- MNPR vs ARQQ Comparison
MNPR vs ARQQ Comparison
Compare MNPR & ARQQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MNPR | ARQQ |
|---|---|---|
| Founded | 2014 | 2017 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 531.6M | 465.3M |
| IPO Year | 2019 | N/A |
Fundamental Metrics
Financial Performance| Metric | MNPR | ARQQ |
|---|---|---|
| Price | $75.05 | $28.33 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 13 | 1 |
| Target Price | ★ $97.83 | $60.00 |
| AVG Volume (30 Days) | 163.8K | ★ 387.3K |
| Earning Date | 11-13-2025 | 12-09-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $530,000.00 |
| Revenue This Year | N/A | $183.60 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $21.00 | $11.00 |
| 52 Week High | $105.00 | $62.00 |
Technical Indicators
Market Signals| Indicator | MNPR | ARQQ |
|---|---|---|
| Relative Strength Index (RSI) | 42.10 | 44.55 |
| Support Level | $74.51 | $27.50 |
| Resistance Level | $79.31 | $31.75 |
| Average True Range (ATR) | 6.38 | 2.26 |
| MACD | -0.93 | 0.68 |
| Stochastic Oscillator | 6.10 | 58.53 |
Price Performance
Historical ComparisonAbout MNPR Monopar Therapeutics Inc.
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicinfor the treatmentof soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.
About ARQQ Arqit Quantum Inc.
Arqit Quantum Inc is a cybersecurity company that has pioneered a symmetric key agreement technology that makes the communications links of any networked device or data at rest secure against current and future forms of cyber attack - even an attack from a quantum computer. The company delivers its symmetric key agreement technology via its product SKA-Platform. The firm operates in one segment that is, the provision of cybersecurity services. The company operates and generates its revenue from UK.